Newsletter | September 2024 Recap

Samsung Biologics launches development platforms for enhanced therapeutic efficacy

Samsung Biologics has launched new development platforms S-AfuCHO? and S-OptiCharge?, designed to enhance therapeutic efficacy. Through these platforms, we reinforce our commitment to delivering high-quality, customized solutions that address evolving industry challenges and drive successful biopharmaceutical development. Read more

How Samsung Biologics achieved 16 top pharma partnerships as a CDMO

Tune into our podcast with Life Sciences 360 featuring Kevin Sharp , Senior Vice President and Head of Global Sales. Gain insights on industry trends and latest innovations, and learn how Samsung Biologics is continuously enhancing its service offerings to meet evolving clients’ needs.

Optimized facilities for flexible, agile manufacturing

Samsung Biologics applies advanced engineering technologies to help clients bring their live-saving medicines to market. In this article, we explore how our specialized facilities are designed to enhance bio-manufacturing capabilities with a focus on flexibility and efficiency. Read more

Virtual technologies to enhance quality mindset and transform learning culture

Ensuring the highest quality in biologics manufacturing starts with advanced employee training. Explore how Samsung Biologics is leveraging VR technology to provide immersive, hands-on training for employees to enhance work efficiency and achieve quality excellence. Read more

Mitigating early development risks with Samsung Biologics DEVELOPICK? platform

Early identification of promising drug candidates is critical for safe and efficient development. In our latest whitepaper, Heonchang Lim , Director of Formulation Development, explains how we leverage our proprietary DEVELOPICK? platform to streamline the discovery process, enhancing the likelihood of successful drug commercialization.?Read more

Improving therapeutic protein efficacy through charge profile adjustment

Charge variants are an important focus of analytical evaluation for mAb therapies. This whitepaper discusses how our advanced charge variant modulation platform, S-OptiCharge?, enables stepwise upstream process development while allowing for precise tuning of charge profiles to meet the target quality specifications of therapeutic proteins. Read more

UPCOMING EVENTS